Navigation Links
Oxitec Responds to University of Panama's 'Forum on Transgenic Mosquitoes'
Date:3/22/2012

LONDON, March 22, 2012 /PRNewswire/ -- The University of Panama held a 'Forum on Transgenic Mosquitoes' on Wednesday 21st March 2012. Unfortunately, all members of the panel at this event have previously registered on repeated occasions as entrenched opposition to the use of transgenic technologies, ensuring that a balanced and productive discussion could not take place. Oxitec, which in 2010 entered into a partnership with the Gorgas Institute in Panama to evaluate a new approach to combating the Dengue mosquito, Aedes aegypti, is disappointed not to have been granted the opportunity to participate fully on this occasion.

At Oxitec we recognise that openness, transparency and public discourse are central to the success of our approach. Oxitec is happy to engage in this process. We hope that in future all public debate will take into account the need for a balanced discussion.

Hadyn Parry, CEO of Oxitec, said:

"As with any new technology, our approach should be examined through expert review and the regulatory process. Experts need to be able to ask questions, and regulators need to determine the conditions for trials. Oxitec is no exception. We see our approach as potentially being an important part in the fight against Dengue.  We are fully committed to the evaluation process and engaging with the public, media and experts. "

To this end, we have taken a number of steps, including:

  • Organization and participation in technical symposia (2009/2010) involving a range of Panamanian and international stakeholders to debate the use of transgenic mosquitoes in Panama as part of a World Health Organisation (WHO) project on genetic control methods against mosquito vectors in disease endemic countries.
  • The organization of a technical symposium (which took place on October 26th , 2011) involving Panamanian academics, government officials, the Pan-American Health Organization and community leaders to debate the use of transgenic mosquitoes in Panama.
  • The organization of a community meeting in Nuevo Chorillo (an area of interest), which took place on November 8th, 2011. This event had an open invitation which allowed us to explain our approach and discuss issues and concerns with members of the public and contribute to media coverage at a local and national level.
  • Complete compliance with Panama's legislation, including the filling of permit applications and detailed briefings (both in writing and in person) presented to national regulatory bodies.

Oxitec is committed to a fully open and transparent relationship with all who wish to find out more about our solutions. Please send any questions to info@oxitec.com, or media enquiries to mediarelations@oxitec.com, tel : +44 (0) 1235 832 393

Notes to editors:

About Oxitec (www.oxitec.com)

Oxitec is a British company pioneering a new approach to combating dengue fever. The Oxitec solution harnesses advanced genetics to create 'sterile' male insects to combat insect-borne diseases. Dengue fever, which at conservative estimate infects at least 50 million people a year, is a growing problem in Panama and across the globe. Currently, mosquito populations are controlled by chemical pesticides which are indiscriminate and have not stopped the spread of the disease. The Oxitec approach has the potential to make a major contribution to global health by combating insects responsible for serious diseases such as dengue fever.


'/>"/>
SOURCE Oxitec
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Squamous Cell Cancer Responds to SPDT Therapy
2. Bunge Responds to Syngenta Suit
3. HCCS Responds to Recent Tornados, Earthquakes and Flooding With Free Online Training Course for Disaster Preparedness
4. Virtual reality helps researchers track how brain responds to surroundings
5. Burrill & Company Responds to Recent Press Coverage About Biopark Investment at Elk Run
6. China Biologic Products Responds to Allegations on Financial Websites
7. Datafarm Responds to Health Canada's Announcement of Hybrid eCTD Submission Procedural Simplification
8. China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports
9. Viral Genetics Responds to Rumors of Imminent FDA Filing and Third Party Press Releases
10. Immucor Responds To FDA Notice
11. Sanofi Pasteur Responds to Nations Need for Hib Vaccine With Increased Supply
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
Breaking Biology News(10 mins):